Clinical Trial Results:
The FACTOR Study (Filanesib and Carfilzomib Treatment of Relapsed/Refractory Multiple Myeloma):
A Multinational, Randomized, Open-label Phase 3 Study of Filanesib (ARRY-520) +
Carfilzomib Versus Single-agent Carfilzomib in Patients With Advanced Multiple Myeloma
Summary
|
|
EudraCT number |
2014-001052-39 |
Trial protocol |
SE AT DE CZ GB HU ES BE GR |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
24 Mar 2022
|
First version publication date |
24 Mar 2022
|
Other versions |
|
Summary report(s) |
2014-001052-39_Cancelled Study |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.